Tempus AI Inc Faces Securities Lawsuits Amid Financial Scrutiny
Overview
Tempus AI, Inc., a technology company specializing in precision medicine through artificial intelligence, is currently embroiled in two class action lawsuits concerning alleged securities fraud. The lawsuits, filed by the Schall Law Firm and the DJS Law Group, claim that Tempus made false and misleading statements to investors during a specified period.
Lawsuit Details
Schall Law Firm Lawsuit: The Schall Law Firm has initiated a class action lawsuit against Tempus AI, Inc. for violations of ยงยง10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The lawsuit targets investors who purchased Tempus securities between August 6, 2024, and May 27, 2025. The firm alleges that Tempus overinflated the value of various contracts, including those with related parties and self-funded agreements. Investors are encouraged to contact the firm before August 12, 2025, to discuss their rights.
DJS Law Group Lawsuit: Similarly, the DJS Law Group has filed a class action lawsuit against Tempus AI, Inc. for securities law violations. The lawsuit claims that Tempus exaggerated the value of several agreements, including those with affiliated entities and internally financed deals. The joint venture with SoftBank is highlighted as potentially undermined by “round-tripping” funds to fabricate revenue. Additionally, the acquisition of Ambry, known for aggressive business practices, is cited as contributing to materially false and misleading public representations.
Company Background
Tempus AI, Inc. operates in the health care sector, focusing on AI-enabled precision medicine solutions. The company provides tools for personalized patient care and supports the discovery, development, and delivery of therapeutics. Its product lines include genomics, data, and AI applications, leveraging next-generation sequencing and other advanced technologies.
Financial Overview
As of July 14, 2025, Tempus AI’s stock closed at $55.89 on the Nasdaq, with a market capitalization of $10.32 billion. The company’s 52-week high was $91.45, and its low was $31.36. The price-to-earnings ratio stands at -7.65, reflecting the financial challenges it faces amid the ongoing lawsuits.
Conclusion
Investors in Tempus AI, Inc. are advised to stay informed about the developments in these lawsuits, as they may impact the company’s financial health and stock performance. Legal counsel can provide guidance on potential participation in the class actions and the implications for shareholders.